# Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

> **NCT06276491** · PHASE1 · RECRUITING · sponsor: **Xencor, Inc.** · enrollment: 282 (estimated)

## Conditions studied

- Ovarian Cancer
- Endometrial Cancer
- Germ Cell Tumor
- Testicular Germ Cell Tumor
- Ovarian Germ Cell Tumor

## Interventions

- **BIOLOGICAL:** XmAb541

## Key facts

- **NCT ID:** NCT06276491
- **Lead sponsor:** Xencor, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-04
- **Primary completion:** 2027-12
- **Final completion:** 2028-12
- **Target enrollment:** 282 (ESTIMATED)
- **Last updated:** 2026-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06276491

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06276491, "Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06276491. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*